Views: 1,566 | Downloads:
111
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Apolipoprotein B Level in patients with Type 2 Diabetes who Achieved Goal of Low Density Lipoprotein Cholesterol and Non-High Density Lipoprotein Cholesterol
Sathavarodom N 
,
Boonyavarakul A
,
Boonyavarakul A Objective: To demonstrate an apolipoprotein B (apo B) level in type 2 diabetic patients who achieved goal of low densitylipoprotein cholesterol (LDL-c) and non-high density lipoprotein cholesterol (non-HDL-c). To identify the percentage of type2 diabetes patients who achieved goal of apo B level.
Material and Method: A cross-sectional study was carried out from 1 October to 31 December 2008. Type2 diabetes patientswho attended at diabetes clinics in the Phramongkutklao hospitals have determined the risk for develop cardiovasculardiseases (CVD) and set up the goal for lipid level according to consensus statement from the American Diabetes Association(ADA) and the American College of Cardiology (ACC) foundation. Blood test for apo B will be done only the patients whoachieved goal of LDL-c and non-HDL-c.
Results: 133 of the 162 registered diabetic patients can achieve goal of lipid level. In this population, 9.7 percent (%) (n = 13)had a history of CVD. Apo B level in diabetic patients with and without CVD is 61.72 + 12.63 and 67.2 + 12.92 milligram perdeciliter (mg/dL), respectively. Nearly ninety-eight percent of patients without cardiovascular diseases (CVD) have achievedapo B (< 90 mg/dL) goal, and 92.3% of patients with CVD have achieved apo B (< 80 mg/dL) goal. The two most commonlyused lipid-lowering agents were statins and fibrates.
Conclusion: In patients with type2 diabetes who achieved goal of LDL-c and non-HDL-c have also achieved apo B level.Thus, apo B measurement in addition to reached LDL-c and non-HDL-c targets may be not necessary especially in diabeticpatients who did not previous CVD.
Keywords: Apolipoprotein B, Type 2 diabetes
Material and Method: A cross-sectional study was carried out from 1 October to 31 December 2008. Type2 diabetes patientswho attended at diabetes clinics in the Phramongkutklao hospitals have determined the risk for develop cardiovasculardiseases (CVD) and set up the goal for lipid level according to consensus statement from the American Diabetes Association(ADA) and the American College of Cardiology (ACC) foundation. Blood test for apo B will be done only the patients whoachieved goal of LDL-c and non-HDL-c.
Results: 133 of the 162 registered diabetic patients can achieve goal of lipid level. In this population, 9.7 percent (%) (n = 13)had a history of CVD. Apo B level in diabetic patients with and without CVD is 61.72 + 12.63 and 67.2 + 12.92 milligram perdeciliter (mg/dL), respectively. Nearly ninety-eight percent of patients without cardiovascular diseases (CVD) have achievedapo B (< 90 mg/dL) goal, and 92.3% of patients with CVD have achieved apo B (< 80 mg/dL) goal. The two most commonlyused lipid-lowering agents were statins and fibrates.
Conclusion: In patients with type2 diabetes who achieved goal of LDL-c and non-HDL-c have also achieved apo B level.Thus, apo B measurement in addition to reached LDL-c and non-HDL-c targets may be not necessary especially in diabeticpatients who did not previous CVD.
Keywords: Apolipoprotein B, Type 2 diabetes
Download:
PDF